Investigation of the efficacy/safety and clinical dose of TAK-390MR for Erosive Esophagitis - A Phase II/III, Stratified-Randomized, Double-Blind, Parallel-Group, Multicenter Study on Efficacy and Safety of TAK-390MR by Comparison with AG-1749 in Patients with Erosive Esophagitis
Phase 2
- Conditions
- Subjects endoscopically diagnosed erosive esophagitis
- Registration Number
- JPRN-jRCT2080220529
- Lead Sponsor
- Takeda Pharmaceutical Company Limited
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 850
Inclusion Criteria
1. Subjects endoscopically diagnosed with Los Angeles grade A-D erosive esophagitis
2. Male or female subject at least 20 years of age at time of obtaining consent
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Healing rate of erosive esophagitis at 8 weeks
- Secondary Outcome Measures
Name Time Method